A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
NCT ID: NCT00219622
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2004-05-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tofimilast
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smoking history of at least 10 pack-years
Exclusion Criteria
* Use of any maintenance therapy except short acting bronchodilators
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Riverside, California, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Riverdale, Georgia, United States
Pfizer Investigational Site
Stockbridge, Georgia, United States
Pfizer Investigational Site
Normal, Illinois, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Wheaton, Maryland, United States
Pfizer Investigational Site
Edina, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Buffalo, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Lake Oswego, Oregon, United States
Pfizer Investigational Site
Lincoln, Rhode Island, United States
Pfizer Investigational Site
Spartanburg, South Carolina, United States
Pfizer Investigational Site
Spartanburg, South Carolina, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Bellingham, Washington, United States
Pfizer Investigational Site
Renton, Washington, United States
Pfizer Investigational Site
Tukwila, Washington, United States
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Vicente López, Buenos Aires, Argentina
Pfizer Investigational Site
Rosario, Santa Fe Province, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Providencia, Santiago Metropolitan, Chile
Pfizer Investigational Site
Recoleta, Santiago Metropolitan, Chile
Pfizer Investigational Site
Santiago, , Chile
Pfizer Investigational Site
ValparaÃ-so, , Chile
Pfizer Investigational Site
San José, Provincia de San José, Costa Rica
Pfizer Investigational Site
México, D.f., Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2641022
Identifier Type: -
Identifier Source: org_study_id